glycosylation reactions

By Targets:	Antibiotic (1) Biochemical Assay Reagents (2) Drug Intermediate (2) Endogenous Metabolite (1) Glycosidase (1) Glycosyltransferase (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (1) Metabolic Disease (4) Neurological Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-NP165

Advanced glycation end products AGEs	Biochemical Assay Reagents	Metabolic Disease
Advanced glycation end products (AGEs) is a series of stable compounds produced by non-enzymatic reactions of reducing sugars with proteins, lipids or nucleic acids. Advanced glycation end products is often used as a target for evaluating the inhibitory effects of anti-glycosylation compounds .

HY-114365

UDP-GalNAc disodium UDP-N-acetyl-D-galactosamine disodium	Endogenous Metabolite	Metabolic Disease Cancer
UDP-GalNAc (UDP-N-acetyl-D-galactosamine) disodium is a sugar nucleotide and a substrate for EpsC115. EpsC115 is a mutant with N-terminal residues 1-115 deleted from the exopolymeric substance (EPS). UDP-GalNAc disodium is a donor substrate for many N-acetylgalactosaminyltransferases, which transfer GalNAc from nucleotide sugars to sugar or peptide acceptors. UDP-GalNAc disodium provides a sugar group donor for glycosylation reactions. UDP-GalNAc disodium can be used in cancer research, such as colorectal and breast cancer .

HY-116284

Methyl β-D-glucopyranoside Methyl β-D-glucoside	Drug Intermediate	Others
Methyl β-D-glucopyranoside (Methyl β-D-glucoside) is a model glycosyl acceptor for enzymatic glycosylation reactions. Methyl β-D-glucopyranoside participates in glycoside synthesis and can react with acyl donors such as caffeic acid esters under the catalysis of specific enzymes (such as Lipozyme TL IM) to achieve acylation modification. Methyl β-D-glucopyranoside can generate biologically active derivatives (such as 6-O-caffeoyl glucoside). Methyl β-D-glucopyranoside can be used in organic synthesis and biocatalysis research, especially the efficient enzymatic preparation of medicinal glycosides (such as Robustaside B (HY-N2720), 6-O-caffeoyl salidroside) .

HY-157461

Glycation-IN-1	Glycosyltransferase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Glycation-IN-1 (Compound 3) is an inhibitor of *glycosylation* reactions, which has a strong inhibitory effect on the synthesis of initial, intermediate, and final products of glycosylation reactions. Glycion-IN-1 can be used in the research of various chronic diseases, such as diabetes, immune inflammation, cardiovascular diseases and neurodegenerative diseases .

HY-W039855A

1,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside, 98%	Biochemical Assay Reagents	Others
1,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside is a substrate for enzymatic glycosylation reactions and glycosyltransferase assays.

HY-125732

Decarestrictine D	Antibiotic	Infection
Decarestrictine D exhibits inhibitory activity against cholesterol levels. Decarestrictine D is utilized as receptor for glycosylation reactions to synthesize novel hybrid antibiotics .

HY-123628

3,4,6-Tri-O-benzyl-β-D-mannopyranose 1,2-(methyl orthoacetate)	Drug Intermediate	Metabolic Disease
3,4,6-Tri-O-benzyl-β-D-mannopyranose 1,2-(methyl orthoacetate) is a synthetic intermediate used in glycosylation reactions .

HY-E70883

Endoglycosidase S (D233Q mutant) EndoS D233Q	Glycosidase	Others
Endoglycosidase S (D233Q mutant) (EndoS D233Q) is a mutant endoglycosidase, which catalyzes the glycosylation of Trastuzumab (HY-P9907)-GlcNAc with the functionalized, non-natural glycans to give glycosylated monoclonal Abs (mAbs) carrying two glycans each functionalized with two reaction handles .

Cat. No.	Product Name	Type

HY-NP165

Advanced glycation end products AGEs	Native Proteins
Advanced glycation end products (AGEs) is a series of stable compounds produced by non-enzymatic reactions of reducing sugars with proteins, lipids or nucleic acids. Advanced glycation end products is often used as a target for evaluating the inhibitory effects of anti-glycosylation compounds .

HY-114365

UDP-GalNAc disodium UDP-N-acetyl-D-galactosamine disodium	Gene Sequencing and Synthesis
UDP-GalNAc (UDP-N-acetyl-D-galactosamine) disodium is a sugar nucleotide and a substrate for EpsC115. EpsC115 is a mutant with N-terminal residues 1-115 deleted from the exopolymeric substance (EPS). UDP-GalNAc disodium is a donor substrate for many N-acetylgalactosaminyltransferases, which transfer GalNAc from nucleotide sugars to sugar or peptide acceptors. UDP-GalNAc disodium provides a sugar group donor for glycosylation reactions. UDP-GalNAc disodium can be used in cancer research, such as colorectal and breast cancer .

UDP-GalNAc disodium

UDP-N-acetyl-D-galactosamine disodium

Gene Sequencing and Synthesis

UDP-GalNAc (UDP-N-acetyl-D-galactosamine) disodium is a sugar nucleotide and a substrate for EpsC115. EpsC115 is a mutant with N-terminal residues 1-115 deleted from the exopolymeric substance (EPS). UDP-GalNAc disodium is a donor substrate for many N-acetylgalactosaminyltransferases, which transfer GalNAc from nucleotide sugars to sugar or peptide acceptors. UDP-GalNAc disodium provides a sugar group donor for glycosylation reactions. UDP-GalNAc disodium can be used in cancer research, such as colorectal and breast cancer .

HY-W039855A

1,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside, 98%	Carbohydrates
1,2,3,4-Tetra-O-benzyl-β-D-glucopyranoside is a substrate for enzymatic glycosylation reactions and glycosyltransferase assays.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-114365

UDP-GalNAc disodium UDP-N-acetyl-D-galactosamine disodium	Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
UDP-GalNAc (UDP-N-acetyl-D-galactosamine) disodium is a sugar nucleotide and a substrate for EpsC115. EpsC115 is a mutant with N-terminal residues 1-115 deleted from the exopolymeric substance (EPS). UDP-GalNAc disodium is a donor substrate for many N-acetylgalactosaminyltransferases, which transfer GalNAc from nucleotide sugars to sugar or peptide acceptors. UDP-GalNAc disodium provides a sugar group donor for glycosylation reactions. UDP-GalNAc disodium can be used in cancer research, such as colorectal and breast cancer .

HY-125732

Decarestrictine D	Human Gut Microbiota Metabolites Microorganisms Macrolide Antibiotics Antibiotics Source classification Endogenous metabolite	Antibiotic
Decarestrictine D exhibits inhibitory activity against cholesterol levels. Decarestrictine D is utilized as receptor for glycosylation reactions to synthesize novel hybrid antibiotics .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Natural
Products